Cargando…
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
To prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (TZDs), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type 2 diabetes who are receiving insulin. The combination of insulin with pioglitazone, a TZD, reduces glycoated he...
Autor principal: | Yamanouchi, Toshikazu |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856574/ https://www.ncbi.nlm.nih.gov/pubmed/20407626 |
Ejemplares similares
-
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Schwartz, Stanley S
Publicado: (2010) -
Risk management in the treatment of type 2 diabetes with pioglitazone
por: Derosa, Giuseppe, et al.
Publicado: (2009) -
Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010) -
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010) -
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007)